SDGR - Schrödinger Inc. (SDGR) Q1 2024 Earnings Call Transcript
2024-05-01 20:28:09 ET
Schrödinger, Inc. (SDGR)
Q1 2024 Earnings Conference Call
May 01, 2024, 16:30 PM ET
Company Participants
Ramy Farid - President and CEO
Geoff Porges - CFO
Karen Akinsanya - President R&D, Therapeutics
Jaren Madden - Senior Vice President, Investor Relations and Corporate Communications
Conference Call Participants
Michael Yee - Jefferies
David Leibowitz - Citi
Scott Schoenhaus - KeyBanc
Vikram Purohit - Morgan Stanley
Conor McKay - BMO
Steven Mah - TD Cowen
Michael Ryskin - Bank of America
Matthew Hewitt - Craig-Hallam Capital
Joseph Catanzaro - Piper Sandler
Chris Shibutani - Goldman Sachs
Presentation
Operator
Welcome to Schrödinger's Conference Call to review First Quarter and 2024 Financial Results. My name is Claudette [ph], and I will be your operator for today's call. Please be advised that this call is being recorded at the company's request.
Now I would like to introduce your host for today's conference, Miss. Jaren Madden, Director of Investor Relations and Corporate Affairs. Please go ahead.
Jaren Madden
Thank you, and good afternoon, everyone. Welcome to today's call, during which we will provide an update on the company and review our first quarter and 2024 financial results. Earlier today, we issued a press release summarizing our financial results and progress across the company, which is available on our website at schrodinger.com.
Here with me on our call today are Ramy Farid, Chief Executive Officer; Geoff Porges, Chief Financial Officer and Karen Akinsanya, President of R&D, Therapeutics. Following our prepared remarks, we'll open the call for Q&A. During today's call, management will make statements that are forward-looking and made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995, including without limitation statements related to our outlook for the second quarter and full year 2024, our plans to accelerate the growth of our software business and advance our collaborative and proprietary drug discovery programs, the timing of, initiation of, and readouts from our clinical trials, the clinical potential and properties of our compounds....
Schrödinger, Inc. (SDGR) Q1 2024 Earnings Call Transcript